AMPH

#2181
Amphastar Pharmaceuticals, Inc. - Common Stock
18.8 5 USD
+9666.84%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
18.85
18.85
年范围
0.18
29.52
日变化
+9666.84%
每月变动
-12.85%
6个月变化
-31.30%
年变化
-22.68%
前一天收盘价
0.1 9
Open
18.8 5
最低价
18.8 5
High
18.8 5
交易量
93
展开完整图表 完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 831.15 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry 药品制造—专业与仿制药
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
13.19
市销率
1.79

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

新闻